Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed type 2 diabetes and obesity management through proven effects on glucose control and weight reduction
Similar content being viewed by others Article Open access09 October 2023 GLP-1-based therapies for diabetes, obesity and beyond Article 25 April 2025 Article Open access13 February 2025 Introduction In recent years, GLP-1R and its agonists have garnered widespread attention in the medical community
SELECT trial: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes 5
Additionally, it possesses anti-inflammatory properties, which can help alleviate inflammation in the nasal passages
In the present study, hypoxic stress resulted in elevated levels of ROS, MDA, and PC in gills, while supplementation with 291.90 to 437.85 mg/kg glutathione reduced their contents, indicating that glutathione alleviated oxidative damage in gill tissue
10.1016/j.gie.2015.08.045 45